Natural Product (NP) Details

General Information of the NP (ID: NP8778)
Name
Morphine
Synonyms
morphine; Morphia; Morphinum; Morphium; Morphin; (-)-Morphine; Morphina; DepoDur; Duromorph; Meconium; Morphinism; Moscontin; Ospalivina; MS Contin; l-Morphine; 57-27-2; Dulcontin; Morfina; Roxanol; MORPHINE SULFATE; Infumorph; Dreamer; Morpho; Avinza; Hocus; Kadian; Unkie; Cube juice; Hard stuff; Statex SR; Ms Emma; Morphin [German]; Morfina [Italian]; Duramorph; Morphina [Italian]; M-Eslon; Morphine [BAN]; Nepenthe; CCRIS 5762; HSDB 2134; (5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol; UNII-76I7G6D29C; CHEBI:17303; CHEMBL70; (5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol; 4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol; 7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol; (7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL; Morphine Anhydrate; 76I7G6D29C; Morphine (BAN); RMS; (5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; Morphinan-3,6-alpha-diol, 7,8-didehydro-4,5-alpha-epoxy-17-methyl-; Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-, (5alpha,6alpha)-; methyl[?]diol; Aguettant; Dinamorf; Sevredol; Dimorf; (5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; (4R,4aR,7S,7aR,12bS)-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol; D-(-)-Morphine; 9H-9,9c-Iminoethanophenanthro(4,5-bcd)furan-3,5-diol, 4a,5,7a,8-tetrahydro-12-methyl-; EINECS 200-320-2; Dolcontin; Oramorph; DEA No. 9300; (Morphine); Anhydrous morphine; N02AA01; Substitol (TN); MOR; (-)-(etorphine); (-)Morphine sulfate; Morfina Dosa (TN); NSC11441; Epitope ID:116646; SCHEMBL2997; BIDD:GT0147; GTPL1627; IDS-NM-009; DTXSID9023336; Morphine 0.1 mg/ml in Methanol; Morphine 1.0 mg/ml in Methanol; ZINC3812983; BDBM50000092; AKOS015966554; DB00295; MOI; C01516; D08233; Hydromorphone hydrochloride impurity, morphine-; Q81225; 7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; UNII-1M5VY6ITRT component BQJCRHHNABKAKU-KBQPJGBKSA-N; 17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol; 7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol(morphine); (5alpha,6beta)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol; 3-(4-Hydroxy-phenyl)-1-propyl-piperidine-3-carboxylic acid ethyl ester; 6-tert-Butyl-3-methyl-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocine; (-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5..alpha.,6.alpha.)-; Morphine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; (1S,5R,13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol; (1S,5R,13R,14S,17R)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10,15-tetraene-10,14-diol; (1S,5R,13R,14S,17R)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7,9,11(18),15-tetraene-10,14-diol; (morphine) 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol; 2-{4-[2,4-diamino-6-pteridinylmethyl(methyl)amino]phenylcarboxamido}pentanedioic acid(morphine); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol; 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol ; HydroChloride; 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol ;sulphate salt(morphine); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol((Morphine)); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(morphine sulfate); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(morphine); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(Morphine)(HCl); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol,sulfate(Morphinesulfate); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diolMorphine; 4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol; 4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol (morphine); 4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(Morphine); 6,11-Dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol(Morphine); 9H-9,9c-Iminoethanophenanthro(4,5-bcd)furan-3,5-diol, 4alpha,5,7alpha,8-tetrahydro-12-methyl-; MORPHINE; (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL; MORPHIUM; MORPHIA; DOLCONTIN; DUROMORPH; MORPHINA; NEPENTHE; Morphine;4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
    Click to Show/Hide
Species Origin Papaver somniferum ...     Click to Show/Hide
Papaver somniferum
Kingdom: Viridiplantae
Phylum: Streptophyta
Class: Magnoliopsida
Order: Ranunculales
Family: Papaveraceae
Genus: Papaver
Species: Papaver somniferum
Disease Pain [ICD-11: MG30-MG3Z] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C17H19NO3
PubChem CID
5288826
Canonical SMILES
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O
InChI
1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2-5,10-11,13,16,19-20H,6-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1
InChIKey
BQJCRHHNABKAKU-KBQPJGBKSA-N
CAS Number
CAS 57-27-2
ChEBI ID
CHEBI:17303
Herb ID
HBIN035767
SymMap ID
SMIT00256
TCMSP ID
MOL006979
TTD Drug ID
D0WE3O
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          Methylphenidate      Attention deficit hyperactivity disorder     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Biological
                    Regulation		 Increase Antinociceptive effect
                    In-vivo Model Adult male Sprague-Dawley rats weighing 250-270 g were used in this study.
                    Experimental
                    Result(s)		 A combination therapy using low-dose MPH and MOR may produce a MOR-sparing effect in chronic pain management.
Target and Pathway
Target(s) Opioid receptor mu (MOR)  Molecule Info  [3]
KEGG Pathway Neuroactive ligand-receptor interaction Click to Show/Hide
2 Estrogen signaling pathway
3 Morphine addiction
NetPath Pathway TCR Signaling Pathway Click to Show/Hide
Panther Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway Click to Show/Hide
2 Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
3 Enkephalin release
Pathway Interaction Database IL4-mediated signaling events Click to Show/Hide
Reactome Peptide ligand-binding receptors Click to Show/Hide
2 G alpha (i) signalling events
WikiPathways TCR Signaling Pathway Click to Show/Hide
2 GPCRs, Class A Rhodopsin-like
3 Peptide GPCRs
4 Opioid Signalling
5 GPCR ligand binding
6 GPCR downstream signaling
References
Reference 1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Reference 2 Methylphenidate and Morphine Combination Therapy in a Rat Model of Chronic Pain. Anesth Analg. 2020 Feb;130(2):518-524.
Reference 3 Antianalgesia: stereoselective action of dextro-morphine over levo-morphine on glia in the mouse spinal cord.J Pharmacol Exp Ther.2005 Sep;314(3):1101-8.
 Download Picture         KEGG Link